UPDATE: Canaccord Lowers LeMaitre Vascular's PT

According to a research report published today, Canaccord has lowered LeMaitre Vascular's LMAT PT to $7.50 following lower-than-expected 4Q results. Canaccord commented in the report, “Q4 results were disappointing with both revenue and operating income much lower than expected. 2012 guidance was also lowered. On a positive note, guidance calls for organic growth of 9%, which is solid for a med tech company in this macro environment. Also, LMAT is also nearly finished with key strategic initiatives it began in 2011. We model OM down in 2012 with some leverage exiting the year. Given LMAT's history, we think that it's likely complementary revenue will be added via acquisition, which is not reflected in our current estimates.” Canaccord maintains its Buy rating on LeMaitre Vascular, which closed yesterday at $5.63.